AstaReal Co., Ltd.

Japan

Back to Profile

1-10 of 10 for AstaReal Co., Ltd. Sort by
Query
Aggregations
IP Type
        Patent 9
        Trademark 1
Jurisdiction
        World 5
        United States 4
        Canada 1
Date
2024 1
2022 1
2021 2
2020 1
Before 2020 5
IPC Class
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin 9
A61K 36/05 - Chlorophycota or chlorophyta (green algae), e.g. Chlorella 5
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives 4
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives 4
A23L 29/10 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing emulsifiers 3
See more
Status
Pending 3
Registered / In Force 7

1.

EMULSION COMPOSITION

      
Application Number 18826623
Status Pending
Filing Date 2024-09-06
First Publication Date 2024-12-26
Owner AstaReal Co., Ltd. (Japan)
Inventor
  • Shitaka, Kazuna
  • Sasaki, Ryoji
  • Sakaguchi, Rina
  • Tominaga, Kumi

Abstract

Provided is an emulsion composition that is capable of enhancing systemic absorption for various carotenoids, well compatible with soft capsules, and capable of being formulated into a soft capsule formulation, and that homogeneously disperses raw materials including carotenoids and emulsifiers in the soft capsule formulation. An emulsion composition containing a carotenoid, and two or more specific emulsifiers selected from the group consisting of tetraglycerin monooleate, decaglycerin monolaurate, sucrose stearate, and sucrose laurate.

IPC Classes  ?

  • A61K 9/107 - Emulsions
  • A23L 29/10 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing emulsifiers
  • A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
  • A23L 33/15 - Vitamins
  • A23L 33/16 - Inorganic salts, minerals or trace elements
  • A61K 8/06 - Emulsions
  • A61K 8/11 - Encapsulated compositions
  • A61K 8/35 - Ketones, e.g. quinones, benzophenone
  • A61K 8/37 - Esters of carboxylic acids
  • A61K 8/60 - SugarsDerivatives thereof
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 31/065 - Diphenyl-substituted acyclic alcohols
  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
  • A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
  • A61Q 19/08 - Anti-ageing preparations

2.

EXERCISE-INDUCED HEMOLYSIS SUPPRESSANT AND COMPOSITION FOR SUPPRESSING/IMPROVING EXERCISE-INDUCED HEMOLYTIC ANEMIA

      
Application Number 17772032
Status Pending
Filing Date 2020-10-29
First Publication Date 2022-11-24
Owner
  • AstaReal Co., Ltd. (Japan)
  • Tokai University Educational System (Japan)
Inventor
  • Hongo, Nobuko
  • Hirashima, Rika
  • Tominaga, Kumi
  • Nishizaki, Yasuhiro

Abstract

[Problem] To provide a composition or the like that suppresses the physical destruction of red blood cells (hemolysis) due to exercises and behaviors associated with impact such as striking, for example, as when continually hitting the soles of the feet on the ground by continued running, by using astaxanthin which has a long history of use as a food, and to provide a composition or the like for making the number of red blood cells destroyed (hemolysis number) to lower than the number of red blood cells newly created by hematopoiesis (hematopoiesis number), to suppress and/or improve exercise-induced hemolytic anemia caused by the physical destruction of red blood cells (hemolysis). [Problem] To provide a composition or the like that suppresses the physical destruction of red blood cells (hemolysis) due to exercises and behaviors associated with impact such as striking, for example, as when continually hitting the soles of the feet on the ground by continued running, by using astaxanthin which has a long history of use as a food, and to provide a composition or the like for making the number of red blood cells destroyed (hemolysis number) to lower than the number of red blood cells newly created by hematopoiesis (hematopoiesis number), to suppress and/or improve exercise-induced hemolytic anemia caused by the physical destruction of red blood cells (hemolysis). [Solution] Astaxanthin is used as an active ingredient.

IPC Classes  ?

  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61P 7/06 - Antianaemics

3.

EXERCISE-INDUCED HEMOLYSIS SUPPRESSANT AND COMPOSITION FOR SUPPRESSING/IMPROVING EXERCISE-INDUCED HEMOLYTIC ANEMIA

      
Application Number JP2020040730
Publication Number 2021/085575
Status In Force
Filing Date 2020-10-29
Publication Date 2021-05-06
Owner
  • ASTAREAL CO., LTD. (Japan)
  • TOKAI UNIVERSITY EDUCATIONAL SYSTEM (Japan)
Inventor
  • Hongo Nobuko
  • Hirashima Rika
  • Tominaga Kumi
  • Nishizaki Yasuhiro

Abstract

[Problem] To provide a composition or the like that suppresses the physical destruction of red blood cells (hemolysis) due to exercise and behaviors associated with impact such as striking, for example, as when continually hitting the soles of the feet on the ground by continued running, by using astaxanthin which has a long history of use as a food, and to provide a composition or the like for making the number of red blood cells destroyed (hemolysis number) lower than the number of red blood cells newly created by hematopoiesis (hematopoiesis number) to suppress and/or improve exercise-induced hemolytic anemia caused by the physical destruction of red blood cells (hemolysis). [Solution] Astaxanthin is used as an active ingredient.

IPC Classes  ?

  • A61P 7/06 - Antianaemics
  • A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
  • A23L 2/52 - Adding ingredients
  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin

4.

EMULSION COMPOSITION

      
Application Number 16978435
Status Pending
Filing Date 2019-03-09
First Publication Date 2021-02-18
Owner AstaReal Co., Ltd. (Japan)
Inventor
  • Shitaka, Kazuna
  • Sasaki, Ryoji
  • Sakaguchi, Rina
  • Tominaga, Kumi

Abstract

Provided is an emulsion composition that is capable of enhancing systemic absorption for various carotenoids, well compatible with soft capsules, and capable of being formulated into a soft capsule formulation, and that homogeneously disperses raw materials including carotenoids and emulsifiers in the soft capsule formulation. An emulsion composition containing a carotenoid, and two or more specific emulsifiers selected from the group consisting of tetraglycerin monooleate, decaglycerin monolaurate, sucrose stearate, and sucrose laurate.

IPC Classes  ?

  • A61K 9/107 - Emulsions
  • A61K 31/065 - Diphenyl-substituted acyclic alcohols
  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
  • A61K 8/35 - Ketones, e.g. quinones, benzophenone
  • A61K 8/11 - Encapsulated compositions
  • A61Q 19/08 - Anti-ageing preparations
  • A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 8/06 - Emulsions
  • A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
  • A61K 8/37 - Esters of carboxylic acids
  • A61K 8/60 - SugarsDerivatives thereof
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A23L 29/10 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing emulsifiers
  • A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
  • A23L 33/15 - Vitamins
  • A23L 33/16 - Inorganic salts, minerals or trace elements

5.

Carotenoid-containing cognitive function improving composition for use in exercise therapy for improving cognitive function

      
Application Number 16666088
Grant Number 11116732
Status In Force
Filing Date 2019-10-28
First Publication Date 2020-02-27
Grant Date 2021-09-14
Owner
  • ASTAREAL CO., LTD. (Japan)
  • UNIVERSITY OF TSUKUBA : (Japan)
Inventor
  • Soya, Hideaki
  • Yook, Jangsoo

Abstract

The present invention relates to a carotenoid-containing composition for use in exercise therapy for improving cognitive function, particularly exercise therapy for hippocampal neurogenesis.

IPC Classes  ?

  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
  • A61K 31/015 - Hydrocarbons carbocyclic
  • A61K 36/05 - Chlorophycota or chlorophyta (green algae), e.g. Chlorella
  • A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
  • A61P 25/00 - Drugs for disorders of the nervous system

6.

EMULSION COMPOSITION

      
Application Number JP2019009549
Publication Number 2019/172454
Status In Force
Filing Date 2019-03-09
Publication Date 2019-09-12
Owner ASTAREAL CO., LTD. (Japan)
Inventor
  • Shitaka Kazuna
  • Sasaki Ryoji
  • Sakaguchi Rina
  • Tominaga Kumi

Abstract

[Problem] To provide an emulsion composition with which it is possible to improve the absorption of various carotenoids into the body, the emulsion composition having excellent compatibility with soft capsules so as to enable soft-capsule preparations to be formed, and raw materials containing carotenoids and emulsifiers are uniformly dispersed into the soft-capsule preparations. [Solution] An emulsion composition containing: a carotenoid; and two or more prescribed emulsifiers selected from the group consisting of tetraglycerin monooleic acid esters, decaglycerin monolauric acid esters, sucrose stearic acid esters, and sucrose lauric acid esters.

IPC Classes  ?

  • A23L 29/10 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing emulsifiers
  • A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
  • A61K 9/107 - Emulsions
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 31/01 - Hydrocarbons
  • A61K 31/015 - Hydrocarbons carbocyclic
  • A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
  • A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
  • A61K 36/05 - Chlorophycota or chlorophyta (green algae), e.g. Chlorella
  • A61K 47/02 - Inorganic compounds
  • A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
  • A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61P 17/18 - Antioxidants, e.g. antiradicals
  • A61P 27/02 - Ophthalmic agents
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
  • A61P 35/00 - Antineoplastic agents
  • A61P 39/06 - Free radical scavengers or antioxidants

7.

USE OF ASTAXANTHIN FOR REDUCING PROGRESSION OF DAMAGE CAUSED TO HUMAN SKIN

      
Application Number JP2017035327
Publication Number 2018/062427
Status In Force
Filing Date 2017-09-28
Publication Date 2018-04-05
Owner ASTAREAL CO., LTD. (Japan)
Inventor
  • Tominaga Kumi
  • Fujishita Mayuko
  • Hongo Nobuko

Abstract

The use of at least any one of astaxanthin and an astaxanthin-containing composition for reducing the progression of damage caused to human skin by an external factor, and a method for reducing the progression of damage caused to human skin by an external factor, the method including allowing astaxanthin to be ingested, each according to the present invention, provide a food-and-drink composition, food-and-drink, pharmaceutical composition, and agent to reduce the worsening of the state of damaged human skin.

IPC Classes  ?

  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
  • A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
  • A61K 36/05 - Chlorophycota or chlorophyta (green algae), e.g. Chlorella
  • A61P 17/16 - Emollients or protectives, e.g. against radiation
  • A61Q 19/00 - Preparations for care of the skin

8.

ASTAREAL

      
Application Number 188503500
Status Registered
Filing Date 2018-02-26
Registration Date 2021-06-01
Owner AstaReal Co., Ltd. (Japan)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical, veterinary and sanitary preparations, namely pharmaceutical, veterinary and sanitary preparations for the treatment of diabetes, for the treatment of dementia, for the treatment of muscle loss, for human and animal skin health, for human and animal eye health, for enhancing muscle performance, for the treatment of cardiovascular diseases, for the treatment of brain health; reagent paper for medical purposes; dietary supplements for general health and well-being for humans, nutritional supplements for general health and well being; dietetic beverages adapted for medical purposes, namely, beverages containing astaxanthin for the treatment and prevention of diabetes, cardiovascular disease, dermatological disease, ocular disease, diseases of the brain, muscular disease, for building body mass, and for promoting weight loss; dietetic food adapted for medical purposes, namely, food containing astaxanthin for the treatment and prevention of diabetes, cardiovascular disease, dermatological disease, ocular disease, diseases of the brain, muscular disease, for building body mass, and for promoting weight loss; dietary supplements for general health and well-being for animals

9.

FOOD OR BEVERAGE COMPOSITION CONTAINING ASTAXANTHIN

      
Application Number JP2017021153
Publication Number 2017/213176
Status In Force
Filing Date 2017-06-07
Publication Date 2017-12-14
Owner ASTAREAL CO., LTD. (Japan)
Inventor
  • Tominaga Kumi
  • Hongo Nobuko
  • Fujishita Mayuko

Abstract

[Problem] To provide a food or beverage composition, a food or beverage and the like which include astaxanthin and/or an astaxanthin-containing extract as an active ingredient. [Solution] A food or beverage composition which includes astaxanthin and/or an astaxanthin-containing extract as an active ingredient can, in healthy men and women experiencing,in particular fatigue due to a mental and physical stress, improve the following symptoms: slowed thinking, decreased concentration, decreased motivation, depression, irritation, physical weakness, and decreased activity and/or energy.

IPC Classes  ?

  • A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
  • A23L 33/115 - Fatty acids or derivatives thereofFats or oils
  • A23L 33/15 - Vitamins
  • A23L 33/155 - Vitamins A or D
  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
  • A61K 31/355 - Tocopherols, e.g. vitamin E
  • A61K 36/05 - Chlorophycota or chlorophyta (green algae), e.g. Chlorella
  • A61K 36/63 - Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61P 25/20 - HypnoticsSedatives
  • A61P 25/24 - Antidepressants
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups

10.

CAROTENOID-CONTAINING COGNITIVE FUNCTION IMPROVING COMPOSITION FOR USE IN EXERCISE THERAPY FOR COGNITIVE FUNCTION IMPROVEMENT

      
Application Number JP2017021203
Publication Number 2017/213197
Status In Force
Filing Date 2017-06-07
Publication Date 2017-12-14
Owner
  • ASTAREAL CO., LTD. (Japan)
  • UNIVERSITY OF TSUKUBA (Japan)
Inventor
  • Soya Hideaki
  • Yook Jangsoo

Abstract

The present invention pertains to a carotenoid-containing composition for use in an exercise therapy for cognitive function improvement, particularly, in an exercise therapy for neogenesis of hippocampal neurons.

IPC Classes  ?

  • A61K 31/015 - Hydrocarbons carbocyclic
  • A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
  • A61K 36/05 - Chlorophycota or chlorophyta (green algae), e.g. Chlorella